跳到正文
原文
STAT Pharma 医药频道· Ed Silverman·· 10 天前AI 评分35

药企在低中收入国家药品可及性方面进展参差不齐

STAT+: Pharma is a ‘mixed bag’ when providing drug access to low- and middle-income countries, analysis finds

AI 导读

多数大型药企正努力改善低中收入国家的药品可及性,但成效不一。目前69%的晚期管线候选药物有患者访问计划,而2018年仅为18%。癌症药物的访问计划覆盖率从2018年的5%升至65%,但非传染性疾病药物的访问计划主要集中在富裕国家。

正文

By Ed Silverman

Nov. 10, 2026

Pharmalot Columnist, Senior Writer

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.

Many large pharmaceutical companies are taking steps to improve access to their medicines in low- and middle-income countries, but progress has been mixed and more action is needed to ensure wide availability, a new analysis found.

Notably, more drugmakers are planning to reach patients before a product launch — access plans now cover 69% of late-stage pipeline candidates compared with 18% in 2018. And across the pipeline, 95% of late-stage experimental drugs developed with a nonprofit partner have an access plan in place, versus 67% without such a partner.

Another bright spot involves cancer treatments. Access plans now cover 65% of cancer drugs in product pipelines, up from 5% in 2018. But 43% of access plans for non-communicable diseases — specifically, sickle cell disease, diabetes, and mental health — focus solely on regulatory registrations and primarily in wealthy countries.

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

来源:STAT Pharma 医药频道 · statnews.com